Publicacións nas que colabora con Isabel Illa Sendra (18)

2022

  1. Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome

    Annals of Clinical and Translational Neurology, Vol. 9, Núm. 2, pp. 122-131

  2. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values

    Clinical Neurophysiology, Vol. 138, pp. 231-240

  3. International Validation of the Erasmus Guillain–Barré Syndrome Respiratory Insufficiency Score

    Annals of Neurology, Vol. 91, Núm. 4, pp. 521-531

  4. Predicting Outcome in Guillain-Barré Syndrome International Validation of the Modified Erasmus GBS Outcome Score

    Neurology, Vol. 98, Núm. 5, pp. E518-E532

2021

  1. Clinical characteristics and outcomes of thymoma-associated myasthenia gravis

    European Journal of Neurology, Vol. 28, Núm. 6, pp. 2083-2091

2019

  1. Current treatment practice of Guillain-Barré syndrome

    Neurology, Vol. 93, Núm. 1, pp. E59-E76

  2. Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, Núm. 5, pp. 576-585

2018

  1. Regional variation of Guillain-Barré syndrome

    Brain, Vol. 141, Núm. 10, pp. 2866-2877

  2. The impact of rituximab infusion protocol on the long-term outcome in anti-MuSK myasthenia gravis

    Annals of Clinical and Translational Neurology, Vol. 5, Núm. 6, pp. 710-716

2017

  1. Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15

    Journal of Neuroinflammation, Vol. 14, Núm. 1

  2. Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain

    Scientific Reports, Vol. 7, Núm. 1

  3. International Guillain-Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain-Barré syndrome

    Journal of the Peripheral Nervous System, Vol. 22, Núm. 2, pp. 68-76

2015

  1. Myasthenia gravis: Descriptive analysis of life-threatening events in a recent nationwide registry

    European Journal of Neurology, Vol. 22, Núm. 7, pp. 1056-1061

  2. Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins

    Neurology: Neuroimmunology and NeuroInflammation, Vol. 2, Núm. 5, pp. e149

2014

  1. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg

    Neurology, Vol. 82, Núm. 10, pp. 879-886

2013

  1. Long-term outcome in chronic inflammatory demyelinating polyneuropathy patients treated with intravenous immunoglobulin: a retrospective study.

    Muscle & nerve, Vol. 48, Núm. 6, pp. 870-876

2012

  1. Guía clínica de la enfermedad de pompe de inicio tardío

    Revista de Neurologia, Vol. 54, Núm. 8, pp. 497-507

2004

  1. Public health surveillance and incidence of adulthood Guillain-Barré syndrome in Spain, 1998-1999: The view from a sentinel network of neurologists

    Neurological Sciences, Vol. 25, Núm. 2, pp. 57-65